Haemophilus influenzae type b conjugate vaccines : a South African perspective

dc.contributor.authorVisser, Adele
dc.contributor.authorHoosen, Anwar Ahmed
dc.contributor.authorHussey, Greg
dc.date.accessioned2012-12-12T11:31:37Z
dc.date.available2012-12-12T11:31:37Z
dc.date.issued2012-09-07
dc.description.abstractIntroduction of Hib vaccine is known to positively impact on reduction of both morbidity and mortality in children less than 5 years of age. Incorporation of this vaccine into a National EPI, however, does come at a significant cost, which is especially important in non-GAVI funded countries. Compounded reduction in response in certain patient populations and possible indication of booster doses further impacts on cost-benefit analyses. Despite these issues, South Africa has supplied Hib vaccine as part of the National EPI in the form of a combination vaccine, Pentaxim®, which combines Hib with Diphtheria, Tetanus, acellular Pertussis (DTP) and Poliomyelitis since 2009. Prior to this, another combination vaccine was utilized containing Hib and DTP. This has subsequently lead to a significant reduction in invasive Hib disease post-introduction, therefore largely justifying utilization.en_US
dc.description.urihttp://www.elsevier.com/locate/vaccineen_US
dc.identifier.citationAdele Visser, Anwar Hoosen & Greg Hussey, Haemophilus influenzae type b conjugate vaccines : a South African perspective, Vaccine, vol. 30, no. s3, pp. C52-C57 (2012), doi: 10.1016/j.vaccine.2012.06.022en_US
dc.identifier.issn0264-410X (print)
dc.identifier.issn1873-2518 (online)
dc.identifier.other10.1016/j.vaccine.2012.06.002
dc.identifier.urihttp://hdl.handle.net/2263/20792
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2012 Elsevier. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Vaccine. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Vaccine, vol 30, issue s3, September 2012, doi: 10.1016/j.vaccine.2012.06.022.en_US
dc.subjectHaemophilus influenzae type ben_US
dc.subjectHIV-1en_US
dc.subjectIntroduction of vaccinesen_US
dc.titleHaemophilus influenzae type b conjugate vaccines : a South African perspectiveen_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Visser_Haemophilus(2012).pdf
Size:
226.91 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: